![Steve Wrenn](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Steve Wrenn is the founder who holds the title of Chief Scientific Officer at Sonnest, Inc. which is founded in 2019.
Steve Wrenn active positions
Companies | Position | Start |
---|---|---|
Sonnest, Inc.
![]() Sonnest, Inc. Medical SpecialtiesHealth Technology Sonnest, Inc. is a company that specializes in developing a contrast agent called Electrast™. The company is based in Baltimore, MD. The inspiration for Electrast™ began in 2015 through a collaboration between Dr. Wrenn, the company's Chief Scientific Officer, and Dr. Brett Angel, an electrophysiologist at Drexel University. Electrast™ is a voltage-activated ultrasound contrast agent that activates with ultrasound and the heart's local electric field if the heart tissue is perfused and viable. The company was founded in 2019 by Steve Wrenn, Brett Angel. The CEO is Peter Boyd. | Founder | 2018-12-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Sonnest, Inc.
![]() Sonnest, Inc. Medical SpecialtiesHealth Technology Sonnest, Inc. is a company that specializes in developing a contrast agent called Electrast™. The company is based in Baltimore, MD. The inspiration for Electrast™ began in 2015 through a collaboration between Dr. Wrenn, the company's Chief Scientific Officer, and Dr. Brett Angel, an electrophysiologist at Drexel University. Electrast™ is a voltage-activated ultrasound contrast agent that activates with ultrasound and the heart's local electric field if the heart tissue is perfused and viable. The company was founded in 2019 by Steve Wrenn, Brett Angel. The CEO is Peter Boyd. | Health Technology |
- Stock Market
- Insiders
- Steve Wrenn